These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27124044)

  • 1. Prognostic Factors Toward Clinically Relevant Radiographic Progression in Patients With Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving a Treat-to-Target Strategy.
    Koga T; Okada A; Fukuda T; Hidaka T; Ishii T; Ueki Y; Kodera T; Nakashima M; Takahashi Y; Honda S; Horai Y; Watanabe R; Okuno H; Aramaki T; Izumiyama T; Takai O; Miyashita T; Sato S; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Origuchi T; Nakamura H; Aoyagi K; Eguchi K; Kawakami A;
    Medicine (Baltimore); 2016 Apr; 95(17):e3476. PubMed ID: 27124044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: A post hoc analysis of a nationwide cohort in Japan.
    Koga T; Okada A; Fukuda T; Hidaka T; Ishii T; Ueki Y; Kodera T; Nakashima M; Takahashi Y; Honda S; Horai Y; Watanabe R; Okuno H; Aramaki T; Izumiyama T; Takai O; Miyashita T; Sato S; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Origuchi T; Nakamura H; Aoyagi K; Eguchi K; Kawakami A;
    PLoS One; 2017; 12(5):e0175281. PubMed ID: 28505163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically relevant radiographic progression in joint destruction in RA patients with abnormal MMP-3 or high levels of CRP despite 1-year treatment with infliximab.
    Nawata M; Saito K; Fukuyo S; Hirata S; Tanaka Y
    Mod Rheumatol; 2016 Nov; 26(6):807-812. PubMed ID: 26915532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
    Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
    JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and functional outcomes of a therapeutic strategy targeting low disease activity in patients with elderly-onset rheumatoid arthritis: a prospective cohort study (CRANE).
    Sugihara T; Ishizaki T; Hosoya T; Iga S; Yokoyama W; Hirano F; Miyasaka N; Harigai M
    Rheumatology (Oxford); 2015 May; 54(5):798-807. PubMed ID: 25296748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheumatoid arthritis patients with low baseline Health Assessment Questionnaire scores have a risk of functional disability progression: a post hoc analysis of a nationwide longitudinal cohort in Japan.
    Sumiyoshi R; Hidaka T; Koga T; Okada A; Fukuda T; Ishii T; Ueki Y; Kodera T; Nakashima M; Takahashi Y; Honda S; Horai Y; Watanabe R; Okuno H; Aramaki T; Izumiyama T; Takai O; Miyashita T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Eguchi K; Kawakami A;
    Clin Exp Rheumatol; 2020; 38(6):1096-1101. PubMed ID: 32896260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    Ten Klooster PM; Versteeg LGA; Oude Voshaar MAH; de la Torre I; De Leonardis F; Fakhouri W; Zaremba-Pechmann L; van de Laar M
    Arthritis Res Ther; 2019 Nov; 21(1):237. PubMed ID: 31718678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.
    Mochizuki T; Yano K; Ikari K; Hiroshima R; Takaoka H; Kawakami K; Koenuma N; Shirahata T; Momohara S
    Mod Rheumatol; 2016 Jul; 26(4):499-506. PubMed ID: 26473281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies.
    Takeuchi T; Soen S; Ishiguro N; Yamanaka H; Tanaka S; Kobayashi M; Okubo N; Nitta T; Tanaka Y
    Mod Rheumatol; 2021 Jan; 31(1):34-41. PubMed ID: 31826682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
    Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
    Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
    Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
    Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study.
    Courvoisier N; Dougados M; Cantagrel A; Goupille P; Meyer O; Sibilia J; Daures JP; Combe B
    Arthritis Res Ther; 2008; 10(5):R106. PubMed ID: 18771585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.
    Meissner Y; Zink A; Kekow J; Rockwitz K; Liebhaber A; Zinke S; Gerhold K; Richter A; Listing J; Strangfeld A
    Arthritis Res Ther; 2016 Aug; 18(1):183. PubMed ID: 27495156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).
    Kaneko Y; Atsumi T; Tanaka Y; Inoo M; Kobayashi-Haraoka H; Amano K; Miyata M; Murakawa Y; Yasuoka H; Hirata S; Nagasawa H; Tanaka E; Miyasaka N; Yamanaka H; Yamamoto K; Takeuchi T
    Ann Rheum Dis; 2016 Nov; 75(11):1917-1923. PubMed ID: 26733110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study.
    Syversen SW; Gaarder PI; Goll GL; Ødegård S; Haavardsholm EA; Mowinckel P; van der Heijde D; Landewé R; Kvien TK
    Ann Rheum Dis; 2008 Feb; 67(2):212-7. PubMed ID: 17526555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
    Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
    Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors for radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs (bDMARDs): Results of 3 to 4 years of follow-up.
    Nakajima A; Terayama K; Sonobe M; Aoki Y; Takahashi H; Akatsu Y; Taniguchi S; Yamada M; Kubota A; Nakagawa K
    Mod Rheumatol; 2019 Nov; 29(6):903-909. PubMed ID: 30285585
    [No Abstract]   [Full Text] [Related]  

  • 19. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan.
    Nishino A; Kawashiri SY; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Kawakami A
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1719-1726. PubMed ID: 29481732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.